Roberto Ramirez-Palacios
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The novel mineralocorticoid receptor modulator balcinrenone protects against diet-induced cardiac microvascular dysfunction and plasma potassium elevation in mouse models.
Journal: PloS one
Published: August 11, 2025
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
Journal: Journal of the American Heart Association
Published: June 06, 2024
Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease.
Journal: Scientific reports
Published: April 29, 2024
Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.
Journal: Clinical science (London, England : 1979)
Published: February 25, 2024
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
Journal: International journal of molecular sciences
Published: December 16, 2022
Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.
Journal: International journal of molecular sciences
Published: May 16, 2022
Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice.
Journal: Frontiers in physiology
Published: January 21, 2022
Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.
Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.
Journal: Scientific reports
Published: January 17, 2019
MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: January 10, 2019
Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade.
Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade.
Journal: The Journal of investigative dermatology
Published: August 29, 2018
Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor.
Journal: The Journal of endocrinology
Published: May 16, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026